CBAY News and Press, CymaBay Therapeutics Inc. From 11/01/23

NEWARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that two-year safety and efficacy results of seladelpar for primary biliary ...

NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, Novem...

2023-10-23 18:16:04 ET Hardly for the first time this year, biotech CymaBay Therapeutics (NASDAQ: CBAY) had a winning day on the market Monday. Following the news that its leading drug candidate had been granted an important designation by a regulator, investors piled into the compa...

Cholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated with seladelpar A second presentation of baseline trial data suggests that any elevation in key liver biomarkers may put PBC patients at risk f...

2023-10-23 10:59:11 ET More on CymaBay Therapeutics CymaBay: Positive Phase 3 Data And Competitive Advantage Established CymaBay Therapeutics: Shares Jump On Confirmatory Seladelpar Data - As Good As It Gets? CymaBay Therapeutics, Inc. (CBAY) Q2 2023 Earnings Call Tr...

NEWARK, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) has revised the originally ...

Results from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13th Fifth oral late-breaking presentation of seladelpar results at The Liver Meeting ® NEWARK, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (...

2023-09-26 16:29:38 ET More on Intercept Pharma Seeking Alpha’s Quant Rating on Intercept Pharma Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) ...

2023-09-21 16:39:43 ET Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . The decline extended a sell-off that began last week following the b...

AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar’s accelerated approval pathway NEWARK, Calif., Sept. 21, 2023 (GLOBE NEWSWIR...